|
NIAID-CDC Joint US Partnership Implementing TB Elimination Research (JUPITER)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
Through weekly teleconferences, the Joint US Partnership Implementing TB Elimination Research (JUPITER) facilitates cooperation, communication, and collaboration on tuberculosis between the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC). This approach helps ensure that Federal activities are coordinated and not duplicated, and stimulates collaborations where appropriate.
|
|
NIAID/CDC Dual Use Research of Concern (DURC) Risk Mitigation Reviews
|
Other
|
CDC
|
NIAID
|
The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins Division will provide technical assistance in evaluating the sufficiency of the biosecurity and/or biosafety measures incorporated into risk mitigation plans received from institutions, and cross-check risk mitigation plans and research conducted using select agents and toxins against information in the Federal Select Agent Program (FSAP) database.
|
|
NIAID/NASA Medical Countermeasures Working Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, FDA
|
NIAID, NCI, NHLBI
|
The purpose of this WG is to bring together experts in radiation countermeasures to look for complementary areas of research across agencies in the following areas: medical countermeasure selection, repurposing, research strategies, and animal models for select endpoints.
|
|
Nicotine Research Cigarettes (SPECTRUM)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
This partnership with the Food and Drug Administration (FDA) is for the production of research cigarettes.
|
|
NIH Guide for Grants and Contracts
|
Resource Development
|
AHRQ, CDC, FDA
|
OD/OER, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI
|
The National Institutes of Health (NIH) Guide for Grants and Contracts is the official publication for NIH medical and behavioral grant policies, guidelines, and funding opportunities. Other US Department of Health and Human Services agencies also use the Guide to disseminate Funding Opportunity Announcements to its 60,000 subscribers.
|
|
NIH Recombinant DNA Advisory Committee (RAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NCI, NHGRI, NIAID, NINDS
|
The Recombinant DNA Advisory Committee (RAC) advises the National Institutes of Health on the safe and ethical conduct of basic and clinical research involving recombinant or synthetic nucleic acid molecules. The Committee reviews and provides recommendations for exceptional human gene transfer protocols to enhance scientific and ethical design. The RAC also provides biosafety guidance for emerging technologies or agents. This year RAC members participated in a meeting to consider the biosafety oversight framework, and whether certain emerging technologies and other areas of life science research may raise scientific, safety, and ethical concerns that should be included in such a system.
|
|
NIH Scientific Data Council for the Common Data Elements (CDE) Task Force
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ
|
NICHD, CC, CIT, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH, OD/OER, OD/OSP
|
The Common Data Elements (CDE) Task Force is charged by the NIH Scientific Data Council to advise it concerning how to improve the communication and coordination of NIH efforts to identify, develop, and promote the use of CDEs in NIH-supported research. Previously, as a working group under the aegis of the Trans-NIH BioMedical Informatics Coordinating Committee (BMIC), the group provided advice to the development of a CDE Repository that serves as a platform for searching, harmonizing, developing, and disseminating CDEs used by NIH Institutes and Centers; Task Force members continue to work with the National Library of Medicine (NLM) to improve this publicly available platform. The Task Force also maintains a web portal with information about NIH-supported CDE initiatives that are intended for use by NIH-funded researchers. The Task Force continues to take steps to encourage the use of CDEs by NIH-funded researchers, minimize overlap and redundancy in CDE initiatives, improve interoperability and compatibility between and among CDE initiatives and with other standards development activities (e.g., related to electronic health records), and assist NIH Institute and Center staff and researchers in identifying and using CDEs that are relevant to their projects.
|
|
NIH Translational Research Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, CC, CIT, CSR, NCATS, NCCIH, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/OER, OD/OIR, OD/OSP
|
As Chair of the National Institutes of Health (NIH) Translational Research Interest Group (TRIG), National Cancer Institute (NCI) staff have coordinated forums, workshops, NIH Bench-to-Bedside Awardees’ Lecture Series, and the Monthly Seminar Series to help bridge the gap between laboratory research and clinical applications; suggest topics and speakers for the Annual NIH Research Festivals; and nominate speakers for the NIH Wednesday Afternoon Lecture Series and the NIH Director’s Lecture Series. NCI staff have informed TRIG members of scientific events coordinated with other NIH scientific interest groups and working groups.
|
|
NIH-CDC-IDSA Guidelines for Treatment of HIV Related Opportunistic Infections Among Adults and Adolescents
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
CC, OD/DPCPSI/OAR
|
The National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and the Centers for Disease Control and Prevention (CDC) have developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immunodeficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV-infected children and previously published guidelines for prevention of OIs in these populations.
|
|
NIH-FDA Interagency Clinical Outcome Assessments (ICOA) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD
|
The Interagency Clinical Outcome Assessments Working Group (ICOA WG) works to foster the development, evaluation, and qualification of Clinical Outcomes Assessments (COAs) for use in both medical product development and clinical research. Leveraging the unique strengths, knowledge, and resources at both the US Food and Drug Administration (FDA) and the National Institutes of Health (NIH), the objectives of the ICOA WG are: (1) To increase communication between the relevant groups at FDA and the many separate efforts at NIH to advance measurement science by exchanging information about specific COA projects of common interest, thereby improving the knowledge base for COA development; (2) To clarify and disseminate information about the regulatory processes for evaluation of medical product development tools; (3) To foster appropriate interagency scientific efforts to generate evidence toward the development and potential qualification of novel COAs; and (4) To leverage public and private efforts toward consensus and standards development in this area. The ICOA WG is composed of representatives and selected senior staff of each agency
|